Background/Aims: Prior work in smaller cohorts suggests that traumatic brain injury (TBI) may be a risk factor for frontotemporal degeneration (FTD). We sought to confirm and extend these results using the National Alzheimer's Coordinating Center Uniform Data Set. Methods: We compared the TBI prevalence between FTD subjects and matched normal controls. Indices of cognitive, behavioral, functional, and global dementia severity were compared between FTD subjects with and without prior TBI. Results: Remote TBI with extended loss of consciousness (TBI-ext) was more common in individuals with FTD than in controls (OR: 1.67; 95% CI: 1.004-2.778). With TBI-ext, less functional and global impairment was seen in the behavioral variant of FTD, but more behavioral pathology was seen in the semantic variant. Conclusion: TBI may increase the FTD risk and influence clinical symptomatology and severity in FTD subtypes.

Keywords:
Brain injuries, Frontotemporal degeneration, Frontotemporal dementia, Frontotemporal lobar degeneration, Primary progressive aphasia, Neuropsychological features in subjects with dementia
1.
Perry DC, Miller BL: Frontotemporal dementia. Semin Neurol 2013;33:336-341.
2.
Mesulam MM: Primary progressive aphasia. Ann Neurol 2001;49:425-432.
3.
Mesulam MM: Primary progressive aphasia - a language-based dementia. N Engl J Med 2003;349:1535-1542.
4.
McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, Santini VE, Lee HS, Kubilus CA, Stern RA: Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009;68:709-735.
5.
Jordan BD: Chronic traumatic brain injury associated with boxing. Semin Neurol 2000;20:179-185.
6.
Bazarian JJ, Cernak I, Noble-Haeusslein L, Potolicchio S, Temkin N: Long-term neurologic outcomes after traumatic brain injury. J Head Trauma Rehabil 2009;24:439-451.
7.
Ishibe N, Wlordarczyk RC, Fulco C: Overview of the Institute of Medicine's Committee search strategy and review process for Gulf War and Health: long-term consequences of traumatic brain injury. J Head Trauma Rehabil 2009;24:424-429.
8.
Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, Guralnik JM, Breitner JC: Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000;55:1158-1166.
9.
Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW: Head injury and Parkinson's disease risk in twins. Ann Neurol 2006;60:65-72.
10.
Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA: Head trauma preceding PD: a case-control study. Neurology 2003;60:1610-1615.
11.
Chen H, Richard M, Sandler DP, Umbach DM, Kamel F: Head injury and amyotrophic lateral sclerosis. Am J Epidemiol 2007;166:810-816.
12.
Strickland D, Smith SA, Dolliff G, Goldman L, Roelofs RI: Physical activity, trauma, and ALS: a case-control study. Acta Neurol Scand 1996;94:45-50.
13.
Onyike CU, Diehl-Schmid J: The epidemiology of frontotemporal dementia. Int Rev Psychiatry 2013;25:130-137.
14.
Rosso SM, Landweer EJ, Houterman M, Donker Kaat L, van Duijn CM, van Swieten JC: Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case-control study. J Neurol Neurosurg Psychiatry 2003;74:1574-1576.
15.
Kalkonde YV, Jawaid A, Qureshi SU, Shirani P, Wheaton M, Pinto-Patarroyo GP, Schulz PE: Medical and environmental risk factors associated with frontotemporal dementia: a case-control study in a veteran population. Alzheimers Dement 2012;8:204-210.
16.
McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, Perl DP, Hedley-Whyte ET, Price B, Sullivan C, Morin P, Lee HS, Kubilus CA, Daneshvar DH, Wulff M, Budson AE: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010;69:918-929.
17.
Smith C, Graham DI, Murray LS, Nicoll JA: Tau immunohistochemistry in acute brain injury. Neuropathol Appl Neurobiol 2003;29:496-502.
18.
Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA: The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210-216.
19.
Bahia V, Takada L, Deramecourt V: Neuropathology of frontotemporal lobar degeneration: a review. Dement Neuropsychol 2013;7:19-26.
20.
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
21.
Folstein MF, Robins LN, Helzer JE: The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
22.
Wechsler D: Wechsler Memory Scale-Revised (WMS-R) Manual. San Antonio, Psychological Corporation, Harcourt Brace Jovanovich Inc, 1987.
23.
Reitan R, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery. Theory and Clinical Interpretation. Tucson, Neuropsychology Press, 1985.
24.
Wechsler D: Wechsler Adult Intelligence Scale-Revised. Digit Symbol Subtest. San Antonio, Psychological Corporation, 1987.
25.
Butters N, Granholm E, Salmon DP, Grant I, Wolfe J: Episodic and semantic memory: a comparison of amnesic and demented patients. J Clin Exp Neuropsychol 1987;9:479-497.
26.
Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test. Philadelphia, Lea and Febiger, 1983.
27.
Shirk SD, Mitchell MB, Shaughnessy LW, Sherman JC, Locascio JJ, Weintraub S, Atri A: A web-based normative calculator for the Uniform Data Set (UDS) neuropsychological test battery. Alzheimers Res Ther 2011;3:32.
28.
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST: Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233-239.
29.
Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S: Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
30.
Teng E, Becker BW, Woo E, Cummings JL, Lu PH: Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2010;30:189-197.
31.
Teng E, Becker BW, Woo E, Knopman DS, Cummings JL, Lu PH: Utility of the Functional Activities Questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:348-353.
32.
Hsiao JJ, Lu PH, Grill JD, Teng E: Longitudinal declines in instrumental activities of daily living in stable and progressive mild cognitive impairment. Dement Geriatr Cogn Disord 2014;39:12-24.
33.
Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
34.
Sayed N, Culver C, Dams-O'Connor K, Hammond F, Diaz-Arrastia R: Clinical phenotype of dementia after traumatic brain injury. J Neurotrauma 2013;30:1117-1122.
35.
Nemetz PN, Leibson C, Naessens JM, Beard M, Kokmen E, Annegers JF, Kurland LT: Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. Am J Epidemiol 1999;149:32-40.
36.
Jawaid A, Rademakers R, Kass JS, Kalkonde Y, Schulz PE: Traumatic brain injury may increase the risk for frontotemporal dementia through reduced progranulin. Neurodegener Dis 2009;6:219-220.
37.
Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R: Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009;132:583-591.
38.
McKee AC, Daneshvar DH, Alvarez VE, Stein TD: The neuropathology of sport. Acta Neuropathol 2014;127:29-51.
39.
Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM, Xuereb JH: The pathological basis of semantic dementia. Brain 2005;128:1984-1995.
40.
Grossman M, Wood EM, Moore P, Neumann M, Kwong L, Forman MS, Clark CM, McCluskey LF, Miller BL, Lee VM, Trojanowski JQ: TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol 2007;64:1449-1454.
41.
Galimberti D, Scarpini E: Genetics of frontotemporal lobar degeneration. Front Neurol 2012;3:52.
42.
Rosen HJ, Allison SC, Ogar JM, Amici S, Rose K, Dronkers N, Miller BL, Gorno-Tempini ML: Behavioral features in semantic dementia vs other forms of progressive aphasias. Neurology 2006;67:1752-1756.
43.
Dams-O'Connor K, Spielman L, Hammond FM, Sayed N, Culver C, Diaz-Arrastia R: An exploration of clinical dementia phenotypes among individuals with and without traumatic brain injury. NeuroRehabilitation 2013;32:199-209.
44.
Hou CE, Yaffe K, Pérez-Stable EJ, Miller BL: Frequency of dementia etiologies in four ethnic groups. Dement Geriatr Cogn Disord 2006;22:42-47.
45.
Pressman PS, Miller BL: Diagnosis and management of behavioral variant frontotemporal dementia. Biol Psychiatry 2014;75:574-581.
46.
Mendez MF, Joshi A, Tassniyom K, Teng E, Shapira JS: Clinicopathologic differences among patients with behavioral variant frontotemporal dementia. Neurology 2013;80:561-568.
47.
Leger GC, Banks SJ: Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia. Dement Geriatr Cogn Disord 2014;37:104-112.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.